Patents by Inventor Willem F. Wolkers

Willem F. Wolkers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6770478
    Abstract: A dehydrated composition is provided that includes freeze-dried erythrocytic cells. Alcohol (e.g., sterol or cholesterol) is at least partially removed from erythrocytic cells including erythrocytic membranes. After removal of at least part of the alcohol, the erythrocytic cells have a low phase transition temperature range, an intermediate phase transition temperature range, and a high phase transition temperature range. The erythrocytic cells may be loaded with an oligosaccharide (e.g., trehalose) which preserves biological properties during freeze-drying and rehydration. A process for increasing cooperativity of a phase transition of an erythrocytic cell. A process for preserving and/or increasing the survival of dehydrated erythrocytic cells, including storing dehydrated erythrocytic cells having a residual water content equal to or less than about 0.30 gram of water per gram of dry weight erythrocytic cells.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: August 3, 2004
    Assignee: The Regents of the University of California
    Inventors: John H. Crowe, Lois M. Crowe, Fern Tablin, Willem F Wolkers, Nelly M. Tsvetkova, Ann F. Oliver
  • Patent number: 6723497
    Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: April 20, 2004
    Assignee: The Regents of the University of California
    Inventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker, Nelly Tsvetkova
  • Publication number: 20020114791
    Abstract: A dehydrated composition is provided that includes freeze-dried erythrocytic cells. Alcohol (e.g., sterol or cholesterol) is at least partially removed from erythrocytic cells including erythrocytic membranes. After removal of at least part of the alcohol, the erythrocytic cells have a low phase transition temperature range, an intermediate phase transition temperature range, and a high phase transition temperature range. The erythrocytic cells may be loaded with an oligosaccharide (e.g., trehalose) which preserves biological properties during freeze-drying and rehydration. A process for increasing cooperativity of a phase transition of an erythrocytic cell. A process for preserving and/or increasing the survival of dehydrated erythrocytic cells, including storing dehydrated erythrocytic cells having a residual water content equal to or less than about 0.30 gram of water per gram of dry weight erythrocytic cells.
    Type: Application
    Filed: January 16, 2002
    Publication date: August 22, 2002
    Inventors: John H. Crowe, Lois M. Crowe, Fern Tablin, Willem F. Wolkers, Nelly M. Tsvetkova, Ann F. Oliver
  • Publication number: 20020076445
    Abstract: A dehydrated composition is provided that includes freeze-dried eukaryotic cells. The eukaryotic cells are loaded with an oligosaccharide (e.g., trehalose) which preserves biological properties during freeze-drying and rehydration. The oligosaccharide loading is conducted at a temperature of from greater than about 25° C. to less than about 50° C., more preferably at about 35° C., with the loading solution having the oligosaccharide in an amount from about 10 mM to about 100 mM. These freeze-dried eukaryotic cells are rehydratable. A process for preserving and/or increasing the survival of dehydrated eukaryotic cells, including storing dehydrated eukaryotic cells having a residual water content greater than about 0.15 gram of water per gram of dry weight eukaryotic cells.
    Type: Application
    Filed: August 9, 2001
    Publication date: June 20, 2002
    Inventors: John H. Crowe, Fern Tablin, Willem F. Wolkers, Ann E. Oliver, Naomi J. Walker, Thurein Htoo, Kamran Jamil
  • Publication number: 20020009500
    Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.
    Type: Application
    Filed: August 23, 2001
    Publication date: January 24, 2002
    Inventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker, Nelly Tsvetkova
  • Publication number: 20010019819
    Abstract: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with the loading solution having trehalose in an amount from about 10 mM to about 50 mM. These freeze-dried platelets are substantially shelf-stable and are rehydratable so as to have a normal response to an agonist, for example, thrombin, with virtually all of the platelets participating in clot formation within about three minutes at 37° C.
    Type: Application
    Filed: April 5, 2001
    Publication date: September 6, 2001
    Inventors: Willem F. Wolkers, John H. Crowe, Fern Tablin, Ann E. Oliver, Naomi J. Walker